Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Jessica E. Ahern"'
Autor:
Elaine Sanij, Katherine M. Hannan, Jiachen Xuan, Shunfei Yan, Jessica E. Ahern, Anna S. Trigos, Natalie Brajanovski, Jinbae Son, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Matthew J. Wakefield, Daniel Frank, Sarah Ellis, Carleen Cullinane, Jian Kang, Gretchen Poortinga, Purba Nag, Andrew J. Deans, Kum Kum Khanna, Linda Mileshkin, Grant A. McArthur, John Soong, Els M. J. J. Berns, Ross D. Hannan, Clare L. Scott, Karen E. Sheppard, Richard B. Pearson
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Acquired resistance limits the efficacy of PARP inhibitors (PARPi) in high grade serous ovarian cancer (HGSOC). Here, the authors show that inhibition of RNA polymerase I transcription using CX-5461 increases the therapeutic efficacy of PARPi and ove
Externí odkaz:
https://doaj.org/article/e147f3013f3440d1be5ac0b31368773d
Autor:
Carleen Cullinane, Olga Kondrashova, Grant A. McArthur, Els M.J.J. Berns, Ross D. Hannan, Katherine M. Hannan, Jessica E. Ahern, Jian Kang, Elaine Sanij, Jinbae Son, Elizabeth Lieschke, John Soong, Keefe T. Chan, Natalie Brajanovski, Anna S Trigos, Karen E. Sheppard, Clare L. Scott, Matthew Wakefield, Linda Mileshkin, Jiachen Xuan, Purba Nag, Richard B. Pearson, Kum Kum Khanna, Andrew J. Deans, Daniel Frank, Shunfei Yan, Gretchen Poortinga, Sarah Ellis
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-18 (2020)
Nature Communications, 11(1). Nature Publishing Group
Nature Communications
Nature Communications, 11(1). Nature Publishing Group
Nature Communications
Acquired resistance to PARP inhibitors (PARPi) is a major challenge for the clinical management of high grade serous ovarian cancer (HGSOC). Here, we demonstrate CX-5461, the first-in-class inhibitor of RNA polymerase I transcription of ribosomal RNA
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3400301f9db041c0069b16de11ebd0d7
http://link.springer.com/article/10.1038/s41467-020-16393-4
http://link.springer.com/article/10.1038/s41467-020-16393-4
Autor:
Purba Nag, Els M.J.J. Berns, Anna S Trigos, Sarah Ellis, Ross D. Hannan, Matthew Wakefield, Jian Kang, Karen E. Sheppard, Richard B. Pearson, Gretchen Poortinga, Clare L. Scott, Jinbae Son, Jiachen Xuan, Grant A. McArthur, John Soong, Carleen Cullinane, Jessica E. Ahern, Elaine Sanij, Linda Mileshkin, Daniel Frank, Shunfei Yan, Keefe T. Chan, Olga Kondrashova, Elizabeth Lieschke, Katherine M. Hannan, Kum Kum Khanna
High-grade serous ovarian cancer (HGSOC) accounts for the majority of ovarian cancer and has a dismal prognosis. PARP inhibitors (PARPi) have revolutionized disease management of patients with homologous recombination (HR) DNA repair-deficient HGSOC.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0bea7a4ef832635064a6a3364dedcc34
https://doi.org/10.1101/621623
https://doi.org/10.1101/621623
Autor:
Amit Khot, Amee J George, Ross D. Hannan, Kum Kum Khanna, Carleen Cullinane, Karen E. Sheppard, Elaine Sanij, Denis Drygin, Jessica E. Ahern, Katherine M. Hannan, Nadine Hein, Richard B. Pearson, Grant A. McArthur, Jeannine Diesch, Ricky W. Johnstone, Donald P. Cameron, Keefe T. Chan, Jaclyn E Quin, Gretchen Poortinga, Jennifer R. Devlin
Publikováno v:
Oncotarget
RNA polymerase I (Pol I)-mediated transcription of the ribosomal RNA genes (rDNA) is confined to the nucleolus and is a rate-limiting step for cell growth and proliferation. Inhibition of Pol I by CX-5461 can selectively induce p53-mediated apoptosis
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::69e97d1ed07cecb28662c09b55661b89
https://doi.org/10.18632/oncotarget.10452
https://doi.org/10.18632/oncotarget.10452